$CYRN,Zacks: Analysts Give Consensus Rating of “Strong

New Post Public Reply Private Reply Replies (0) Message Board
fitzkarz
$CYRN,Zacks: Analysts Give Consensus Rating of “Strong Buy” to Cyren (NASDAQ:CYRN)

Posted by Shayan Afkhami on Mar 22nd, 2015 // No Comments
Share on StockTwits

Cyren logoShares of Cyren (NASDAQ:CYRN) have been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Brokers have set a twelve-month consensus target price of $5.00 for the company and are predicting that the company will post ($0.02) EPS for the current quarter, according to Zacks. Zacks has also assigned Cyren an industry rank of 72 out of 265 based on the ratings given to related companies.

Separately, analysts at Zacks reiterated an “outperform” rating and set a $5.00 price target on shares of Cyren in a research note on Wednesday, February 25th.

Cyren (NASDAQ:CYRN) opened at 2.79 on Thursday. Cyren has a 52 week low of $1.40 and a 52 week high of $3.79. The stock’s 50-day moving average is $2. and its 200-day moving average is $2.. The company’s market cap is $87.53 million.

Cyren (NASDAQ:CYRN) last announced its earnings results on Tuesday, February 24th. The company reported ($0.04) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.03) by $0.01. The company had revenue of $7.80 million for the quarter, compared to the consensus estimate of $8.20 million. During the same quarter in the prior year, the company posted ($0.07) earnings per share. The company’s quarterly revenue was down 5.0% on a year-over-year basis.

Cyren Ltd, formerly Commtouch Software Ltd., is a provider of messaging, antivirus and Web security solutions to a range of customers and original equipment manufacturer (NASDAQ:CYRN) and service provider distribution partners.

To get a free copy of the research report on Cyren (CYRN), click here. For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cyren Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyren and related companies with Analyst Ratings Network's FREE daily email newsletter.
I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 52

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 63

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 37

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 40

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 46

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 28

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 35

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading

Top 5 Most Recently Viewed Articles

NORBIT Secures Significant NOK 120M Defence Order

Updated Category News Views 288

NORBIT Secures Significant NOK 120 Million Defence Order NORBIT has recently made an exciting announcement regarding a significant contract within its segment PIR. The company has been awarded a manufacturing order valued at NOK 120 million from a European client specializing in defence and security. This order is poised for delivery in late 2025 and early 2026, marking a...

Continue Reading
Shareholder Concerns Over BCO, SEM, NATL Transactions

Updated Category News Views 12

Is There Smoke Without Fire in Recent Company Mergers? Well, here we go again. It seems every time deals like these pop up, questions start flying about fairness and insider scoops. The big fish here? The Brink's Company (NYSE:BCO), Select Medical Holdings Corporation (NYSE:SEM), and NCR Atleos Corporation (NYSE:NATL). Halper Sadeh LLC, the investor rights firm, is on a...

Continue Reading
TG Therapeutics Director’s Recent Stock Sale Raises Questions

Updated Category News Views 120

Significant Insider Transaction at TG Therapeutics Recently, an important transaction came to light involving Yann Echelard, Director at TG Therapeutics (NASDAQ:TGTX). The details were revealed through the latest SEC filing. On a given date, Echelard sold 5,000 shares, raising a total of $162,850. Such insider trading can often prompt discussions regarding the company’s...

Continue Reading
Innovative Leadership in Facilities Management Revolutionized

Updated Category News Views 214

MasonMade Ventures Launches to Revamp Facilities Management Serial Entrepreneurs Aim to Disrupt the FM Industry through Innovative Software Solutions and Expert Trades MasonMade Ventures, established by visionary entrepreneurs Joseph Scaretta and Moses Carrasco, is set to change the face of facilities management. This operational holding company focuses on investing in...

Continue Reading
Kyverna Therapeutics Engages Investors at Upcoming Events

Updated Category News Views 136

Kyverna Therapeutics' Upcoming Investor Conferences Kyverna Therapeutics, Inc. (NASDAQ: KYTX), a pioneering clinical-stage biopharmaceutical company committed to innovative cell therapies for autoimmune diseases, is slated to present at a series of significant investor conferences this September. Warner Biddle, the Chief Executive Officer of Kyverna, will be the...

Continue Reading